Prevalence and Symptomatic Benefit of Antibiotic Use in End-of-Life Patients in Saudi Arabia: An Observational Cohort Study
Journal of Palliative Care · 2025
DOI: 10.1177/08258597251336821 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Journal of Palliative Care, 2025. Verfasst von Seham Radhi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Palliative Care, King Fahed Medical City, Riyad, Saudi Arabia. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Terminal Care, Palliative Care, Neoplasms. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objectives
Antibiotic use in patients with advanced cancer at the end of life (EoL) is common but controversial, with limited evidence on its efficacy in improving symptoms. This study aimed to evaluate the prevalence of antibiotic use during the final 30 days of life in patients with advanced cancer and its impact on symptom improvement within a palliative care setting in Saudi Arabia.
Methods
A retrospective cohort study was conducted in the palliative care department of King Fahad Medical City, Riyadh, Saudi Arabia. The study included all advanced cancer patients who received inpatient palliative care and died between January 2022 and March 2023. Medical records data were analyzed to assess infection-related symptoms, antibiotic use, and symptom improvement 3 days (D3) post-diagnosis.
Results
A total of 220 patients were included, with a mean age of 61 ± 17 years and a mean palliative performance scale of 37%. Antibiotics were prescribed to 89% of patients, primarily empirically (82%). Piperacillin/tazobactam (53%) and meropenem (17%) were the most commonly used antibiotics. Symptom improvement at D3 was observed in 54% of symptomatic patients (n = 95). Improvements were significant for fever (42% to 15%, P < .001), pain (58% to 37%, P < .001), cough (16% to 7%, P = .004), and shortness of breath (32% to 20%, P = .003). The logistic regression model analysis identified no significant predictors of symptom improvement.
Conclusion
Antibiotics are widely used EoL care for advanced cancer patients, but their impact on symptom improvement is modest. The findings underscore the need for judicious antibiotic use, guided by individualized care goals and interdisciplinary collaboration, to optimize symptom management while minimizing unnecessary interventions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Palliative Care, King Fahed Medical City, Riyad, Saudi Arabia.
- College of Medicine, Alfaisal University, Riyad, Saudi Arabia.
- Department of Cardiovascular Sciences, University of Leicester, Leicester, UK.
ORCID-Profile: Ibrahim Antoun
Zitieren
APA
Radhi, S., Alamri, M. A., Ksibati, A. A., Shahda, N. A., Alsuhail, A. I., Zakkar, M., & Antoun, I. (2025). Prevalence and Symptomatic Benefit of Antibiotic Use in End-of-Life Patients in Saudi Arabia: An Observational Cohort Study. Journal of Palliative Care. https://doi.org/10.1177/08258597251336821
Vancouver
Radhi S, Alamri MA, Ksibati AA, Shahda NA, Alsuhail AI, Zakkar M, et al. Prevalence and Symptomatic Benefit of Antibiotic Use in End-of-Life Patients in Saudi Arabia: An Observational Cohort Study. Journal of Palliative Care. 2025. doi:10.1177/08258597251336821
BibTeX
@article{Radhi2025,
author = {Radhi, Seham and Alamri, Mohammed A and Ksibati, Abdurrahman A and Shahda, Nadia A and Alsuhail, Abdullaha I and Zakkar, Mustafa and Antoun, Ibrahim},
title = {Prevalence and Symptomatic Benefit of Antibiotic Use in End-of-Life Patients in Saudi Arabia: An Observational Cohort Study},
journal = {Journal of Palliative Care},
year = {2025},
doi = {10.1177/08258597251336821}
}
EUVIMED